News
HBIO
3.970
-2.93%
-0.120
Weekly Report: what happened at HBIO last week (0408-0412)?
Weekly Report · 3d ago
Harvard Bioscience announces labor force reduction
Healthcare Harvard Bioscience announces labor force reduction. Company expects to realize annual run rate savings of approximately $4M beginning in the second quarter of 2024. The company also expects second quarter restructuring-related charges of about $0.5M. Harvard bioscience (NASDAQ:HBIO) stock.
Seeking Alpha · 04/09 13:28
HARVARD BIOSCIENCE INC: LABOR FORCE REDUCTION TO IMPROVE ITS OPERATING COST STRUCTURE AND SUPPORT ITS ONGOING INVESTMENTS IN GROWTH
Reuters · 04/09 13:00
Weekly Report: what happened at HBIO last week (0401-0405)?
Weekly Report · 04/08 09:53
Weekly Report: what happened at HBIO last week (0325-0329)?
Weekly Report · 04/01 09:53
Harvard Bioscience Sets Incentive Plan for Top Executives
TipRanks · 03/26 21:12
Weekly Report: what happened at HBIO last week (0318-0322)?
Weekly Report · 03/25 09:54
Weekly Report: what happened at HBIO last week (0311-0315)?
Weekly Report · 03/18 09:53
Weekly Report: what happened at HBIO last week (0304-0308)?
Weekly Report · 03/11 09:52
HBIO Stock Earnings: Harvard Bioscience Misses EPS, Misses Revenue for Q4 2023
Harvard Bioscience reported earnings per share of 4 cents. The company reported revenue of $28.15 million. This was 3.29% below the analyst estimate of $29.11 million for the company's quarterly report. The stock was down 2.7% after the market closed.
Investorplace · 03/07 17:53
Harvard Bioscience Inc reports results for the quarter ended in December - Earnings Summary
Harvard Bioscience Inc reported quarterly adjusted earnings of 4 cents per share for the quarter ended in December. Revenue fell 1% to $28.15 million from a year ago. The company reported a quarterly loss of $1.82 million. Harvard Biosscience Inc shares had fallen by 23.2% this quarter.
Reuters · 03/07 15:15
Harvard Bioscience Non-GAAP EPS of $0.04 misses by $0.01, revenue of $28.2M misses by $0.4M
Seeking Alpha · 03/07 12:02
Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate
Harvard Bioscience reported quarterly earnings of Adj $0.04 per share. The company reported quarterly sales of $28.15 million. Harvard missed the analyst consensus estimate of $29.11 million by 3.29%. The company's sales for the quarter were unchanged from the same period last year.
Benzinga · 03/07 12:02
*Harvard Bioscience Sees Flat to Modest Revenue Growth for FY24>HBIO
Dow Jones · 03/07 12:02
*Harvard Bioscience 4Q Rev $28.2M >HBIO
Dow Jones · 03/07 12:00
*Harvard Bioscience 4Q Adj EPS 4c >HBIO
Dow Jones · 03/07 12:00
Press Release: Harvard Bioscience Announces -2-
Harvard Bioscience, Inc. Is a leading developer, manufacturer and seller of technologies, products and services that enable advances in life science applications. The company's products are used in research, pharmaceutical and therapy discovery, bio-production and preclinical testing. This document contains forward-looking statements.
Dow Jones · 03/07 12:00
*Harvard Bioscience 4Q Loss/Shr 4c >HBIO
Dow Jones · 03/07 12:00
Press Release: Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results. Q4 Revenues of $28.2 million. Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million. Strong operating cash flow enabled 2023 debt reduction of $10.5 million.
Dow Jones · 03/07 12:00
Earnings Scheduled For March 7, 2024
CI&T is expected to report quarterly earnings at $0.06 per share on revenue of $106.08 million. Other companies expected to release earnings before the bell include Burlington Stores, American Eagle Outfitters and Bilibili. The companies will also be reporting earnings for their third quarter.
Benzinga · 03/07 09:49
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.